Beyond current successes, Eli Lilly is innovating with a potential game-changing oral GLP-1, orforglipron. Read why I ...

Wall Street’s major market averages seesawed back and forth on Friday and finished mixed as Federal Reserve Governor ...

Eli Lilly's stock price has over-corrected following a downgrade in its outlook following the adjustment for acquisition ...

Eli Lilly will buy Boston-based Verve Therapeutics, Inc. in a billion dollar deal with plans to advance Verve's new line of ...

The acquisition aligns with Eli Lilly’s broader diversification strategy beyond its core diabetes and obesity treatment ...

Eli Lilly said the response for its blockbuster drug Mounjaro has been "positive" in India, adding that it is focusing on ...

Verve Therapeutics’ stock was rallying by a record 80% on Eli Lilly’s premium purchase price for the drug-development company ...

Boston-based Verve is a rare example of a gene-editing company targeting a disease that affects a large population, offering ...

Eli Lilly will acquire Verve Therapeutics for up to $1.3 billion, the companies said on Tuesday. Verve is developing ...

Baron Funds, an investment management company, released its “Baron Fifth Avenue Growth Fund” first quarter 2025 investor ...

Eli Lilly will acquire gene-editing startup Verve Therapeutics for up to $1.3 billion, the companies said on Tuesday, sending ...

Eli Lilly is looking to approach regulatory approval of efsitora alfa (efsitora), its once-weekly insulin for type 2 diabetes ...